Literature DB >> 15689747

Thyroglobulin before ablation and correlation with posttreatment scanning.

Pedro Weslley Souza de Rosário1, Valéria C Guimarães, Frederico Fernandes Ribeiro Maia, Tales Alvarenga Fagundes, Saulo Purisch, Eduardo Lanza Padrao, Leonardo Lamego Rezende, Alvaro Luis Barroso.   

Abstract

OBJECTIVES/HYPOTHESIS: To determine the usefulness of thyroglobulin (Tg) before ablation and the correlation with posttreatment scanning in patients with thyroid carcinoma. STUDY
DESIGN: Prospective.
METHODS: Tg during hypothyroidism was determined in 212 patients after thyroidectomy and before ablation. The disease stage was based on clinical examination, Tg, posttherapy scanning, other imaging methods, and histologic confirmation in selected cases.
RESULTS: One hundred sixty-four patients presented thyroid remnants only, 31 had lymph node metastases, and 17 had distant metastases. Posttreatment scanning showed a sensitivity of 71% for lymph node and of 94.1% for distant metastases. Ectopic uptake was observed in 5.6% of patients with Tg less than 1 ng/mL, in 9% with levels from 1 to 5 ng/mL, in 10.7% with Tg from 5 to 10 ng/mL, and in 51% with Tg greater than 10 ng/mL. The sensitivity of Tg for metastases was 73 and 66.5% and specificity was 73 and 88.4% at a cut-off value of 5 and 10 ng/mL, respectively.
CONCLUSIONS: Postoperative Tg less than 10 ng/mL rarely show distant metastases and because these metastases were observed in 31% of patients with values greater than 10 ng/mL, this criterion can be selected for the indication of imaging methods, in addition to neck ultrasound (US). For cases with Tg less than 10 ng/mL, US is necessary because even patients with undetectable Tg had lymph node metastases. The same cut-off can be used for the indication of radioiodine therapy even in the absence of any evidence of disease because 51% of the patients with Tg greater than 10 ng/mL showed ectopic uptake on posttreatment scanning.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689747     DOI: 10.1097/01.mlg.0000154730.31281.0c

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  Usefulness of repeated recombinant human thyrotropin-stimulated thyroglobulin test in the post-surgical follow-up of very low-risk patients with differentiated thyroid carcinoma.

Authors:  C Cappelli; M Rotondi; I Pirola; E De Martino; E Gandossi; B Agosti; E Agabiti Rosei; L Chiovato; M Castellano
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

2.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience.

Authors:  Ayanthi Wijewardene; Matti Gild; Carolina Nylén; Geoffrey Schembri; Paul Roach; Jeremy Hoang; Ahmad Aniss; Anthony Glover; Mark Sywak; Stan Sidhu; Diana Learoyd; Bruce Robinson; Lyndal Tacon; Roderick Clifton-Bligh
Journal:  Eur Thyroid J       Date:  2021-05-25

5.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

6.  99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study.

Authors:  Min Liu; Li Chai; Qiong Luo; Maomei Ruan; Lingxiao Cheng; Zhongwei Lv; Libo Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

7.  Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.

Authors:  Alfredo Campennì; Luca Giovanella; Salvatore Antonio Pignata; Antonio Vento; Angela Alibrandi; Letterio Sturiale; Riccardo Laudicella; Alessio Danilo Comis; Rossella Filice; Giuseppe Giuffrida; Maria Elena Stipo; Salvatore Giovinazzo; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Sergio Baldari
Journal:  Oncotarget       Date:  2018-04-03

8.  Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.

Authors:  Chang-Hee Lee; Ji-Hoon Jung; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  PLoS One       Date:  2018-08-17       Impact factor: 3.240

9.  Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives.

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Eur Thyroid J       Date:  2018-11-16

10.  Role of Preablative Stimulated Thyroglobulin in Prediction of Nodal and Distant Metastasis on Iodine Whole-Body Scan.

Authors:  Meghana Prabhu; Sanju Samson; Avinash Reddy; Sunil Hejaji Venkataramanarao; Naveen Hedne Chandrasekhar; Vijay Pillai; Vivek Shetty; Moni Abraham Koriokose; Bushan Vaidhya; Subramanian Kannan
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.